QCG
MRTX

Quadrant Capital Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Quadrant Capital Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-515
Closed -$30.3K – 2803
2023
Q4 		$30.3K Buy
515
+381
+284% +$21.4K ﹤0.01% 1632
2023
Q3 		$5.84K Sell
134
-122
-48% -$4.36K ﹤0.01% 2134
2023
Q2 		$9.25K Buy
256
+180
+237% +$7.42K ﹤0.01% 2022
2023
Q1 		$2.83K Sell
76
-390
-84% -$17.5K ﹤0.01% 2363
2022
Q4 		$21.1K Sell
466
-536
-53% -$34.7K ﹤0.01% 1634
2022
Q3 		$70K Buy
1,002
+301
+43% +$22.3K 0.01% 872
2022
Q2 		$47K Buy
701
+433
+162% +$27.5K 0.01% 901
2022
Q1 		$22K Buy
268
+255
+1,962% +$26.1K ﹤0.01% 1297
2021
Q4 		$2K Sell
13
-39
-75% -$6.05K ﹤0.01% 2206
2021
Q3 		$9K Buy
52
+38
+271% +$6.11K ﹤0.01% 1671
2021
Q2 		$2K Sell
14
-2
-13% -$321 ﹤0.01% 2179
2021
Q1 		$3K Sell
16
-19
-54% -$3.76K ﹤0.01% 2006
2020
Q4 		$8K Buy
+35
New +$7.57K ﹤0.01% 1528
2017
Q2 		– Sell
-989
Closed -$5K – 2105
2017
Q1 		$5K Hold
989
– – ﹤0.01% 1353
2016
Q4 		$4K Buy
+989
New +$5.38K ﹤0.01% 1334

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quadrant Capital Group's MRTX Position: Q1 2024 in Review

Quadrant Capital Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 515 shares — an estimated $30.3K sold.

Quadrant Capital Group first reported a position in MRTX in Q4 2016 and held it in 15 quarters. The position peaked at $70K in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Quadrant Capital Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 515 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $30.3K.
  • Quadrant Capital Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2016 and held it in 15 quarters.
  • Quadrant Capital Group's Mirati Therapeutics, Inc. Common Stock position peaked at $70K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Quadrant Capital Group's 13F filing for Q1 2024, filed 15 May 2024.